Luminal Metastatic Breast Cancer
نویسندگان
چکیده
منابع مشابه
Clinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...
متن کاملAn unusual metastatic breast cancer presentation Report of a case
ABSTRACTWe are reporting a 43-year-old female breast cancer case with a solitary metastatic adenocarcinoma in clivus. This patient with a stage II (T1N1M0) breast cancer history has been followed for 7 years. Modified Radical Mastectomy (MRM) and 6 courses chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5FU) regimen were done for her at the time of diagnosis. Also, she took tamoxifen tw...
متن کاملMicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells
MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR-200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with ...
متن کاملGenomic profiling in luminal breast cancer.
The developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no...
متن کاملCDK4/6 inhibition in luminal breast cancer
Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are aimed to overcome endocrine resistance. The selective CDK4/6 inhibitor palbociclib has shown prom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Care
سال: 2019
ISSN: 1661-3791,1661-3805
DOI: 10.1159/000499440